Research Paper Volume 15, Issue 20 pp 11588—11610
Immunobiological signatures and the emerging role of SPP1 in predicting tumor heterogeneity, malignancy, and clinical outcomes in stomach adenocarcinoma
Figure 6. Prognostic validation of risk signature. (A–C) Kaplan–Meier survival analysis with p-value < 0.05 indicating that the established risk signature can identify high- and low-risk groups. (D–F) Scatter plots showing the relationship between risk score and survival time. (G–I) ROC curve to predict the accuracy of the patient's one-year, three-year, and five-year survival rate.